DOV says bicifadine eliminates carcinogens

By Elaine Rigoli

Tampa, Fla., July 26 - DOV Pharmaceutical, Inc. said the results from the carcinogenicity studies for its novel analgesic, bicifadine, showed that no carcinogenicity was detected after two years of testing in two species - rats and mice.

The company said these results are very positive, as this outcome will support its New Drug Application with the Food and Drug Administration and other regulatory agencies worldwide.

"While this package must also be reviewed by experts at U.S. and international regulatory agencies, both our internal experts and external team of consultants are pleased with the outcome of these studies," said Joseph Tizzano, senior director of toxicology, in a news release.

"The safety of bicifadine in these long-term carcinogenicity studies compares favorably to many drugs currently marketed to treat chronic pain conditions, including neuropathic pain," he said.

DOV is a biopharmaceutical company located in Somerset, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.